Kenmare Resources PLC (KMR)
London Stock Exchange · UK · prices in GBX · close of 27 Oct 2026
Key indicators
| Last close | GBX 228.00 |
|---|---|
| 52-week range | 171.40 – 292.00 |
| Return, 1 month / 3 months | +24.6% / +19.4% |
| Return, 1 year / 3 years | −14.6% / −31.2% |
| Trend | Uptrend |
| RSI (14) | 60 |
| Volatility (1 year) | 49.7% |
| Worst drawdown (1 year) | -37.8% |
| Average daily value traded | 21.59M GBX |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Kenmare Resources is a mineral sands mining company based in Dublin, Ireland, whose main operation is the Moma mine in northern Mozambique. The company extracts and processes heavy mineral sands to produce ilmenite, rutile and zircon, which are used as raw materials by customers in the pigment, ceramics and titanium metal industries. Its products are shipped to industrial buyers around the world, and the business centres on dredge mining and mineral separation at its coastal site.
The shares are listed on the London Stock Exchange in UK under the code KMR, and the price on this page is in pence sterling (GBX). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Kenmare Resources PLC (KMR) trades on the London Stock Exchange in UK. It last closed at GBX 228.00 on 27 October 2026.
Its price-based Market X-Ray is 47 out of 100 (a weak price profile), ranking 2,223 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 14.6% and over the last three months it rose 19.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 43 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | 4.6% | ||
| From 52-week high | -20.7% | ||
| Momentum | 48 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | 19.4% | ||
| 6-month return | -1.7% | ||
| 12-month return, skipping the last month | -31.5% | ||
| Stability (higher is calmer) | 31 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 49.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.8% | ||
| Liquidity | 80 · Strong | Trades actively. | |
| Average daily value traded | 21.59M GBX | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +1.3% |
|---|---|
| 1 month | +24.6% |
| 3 months | +19.4% |
| 6 months | −1.7% |
| 1 year | −14.6% |
| 3 years | −31.2% |
| 5 years | −26.4% |
Signals
| 50-day / 200-day average | 201.34 / 217.92 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 12.57 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 Sep 2025 | GBP 0.0750 |
| 8 May 2025 | GBP 0.1275 |
| 19 Sep 2024 | GBP 0.1125 |
| 11 Apr 2024 | GBP 0.2891 |
| 21 Sep 2023 | GBP 0.1313 |
| 13 Apr 2023 | GBP 0.3251 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.